Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, ...

Objectives This study describes the prototype testing and clinical validation of the Fit-Frailty App, a fully guided, interactive mobile health (mHealth) app to assess frailty and sarcopenia. This ...

By utilizing a standardized methodology for evaluating novel digital measures, sDHT developers, biostatisticians and clinical researchers will be able to navigate the complex validation landscape more ...

NEW YORK – Personalized cancer firm Artera this week presented four studies on its multimodal artificial intelligence (MMAI) digital pathology-based risk stratification platform at the annual ...

Health care leaders may want to keep a closer eye on clinical validation for artificial intelligence (AI)-enabled medical devices (AIMDs), based on a recent JAMA Health Forum study. The study examined ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

Artificial intelligence-enabled medical devices with no clinical validation were more likely to be the subject of recalls, according to a study published in JAMA Health Forum. The study, published on ...